相关实验视频
Updated: Jan 11, 2026

09:18
A Gut-on-a-Chip Model to Study the Gut Microbiome-Nervous System Axis
Published on: July 28, 2023
3.4K
将肠道微生物群纳入糖尿病神经病变的多学科视角
Maksym Horiachok1, Kateryna Potapova1,2, Taras Ivanykovych1,3
1Global Medical Knowledge Alliance, Boston, MA, United States.
Frontiers in endocrinology
|November 19, 2025
概括
肠道微生物群影响糖尿病神经病变 (DN) 的发展和进展. 基于微生物组的诊断和治疗为管理这种常见的糖尿病并发症提供了新的希望.
科学领域:
- 微生物学 微生物学
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 糖尿病神经病变 (DN) 是糖尿病的常见并发症,其发病因子尚未完全理解.
- 人们越来越认识到肠道微生物组是代谢功能障碍,免疫激活和神经元损伤的关键因素.
- 肠道失调可以导致炎症和通过肠道-大脑-免疫轴改变疼痛反应.
研究的目的:
- 综合目前关于肠道微生物群在糖尿病神经病变中的作用的证据.
- 突出微生物组作为诊断生物标志物和DN治疗点的潜力.
- 审查DN管理的新兴基于微生物组的干预措施.
主要方法:
- 审查最近的临床和临床前数据.
- 分析从元基因组学和代谢学研究的发现.
- 关于受微生物群影响的干预措施的证据综合.
主要成果:
- 减少短链脂肪酸的可用性,改变胆酸和酸代谢,以及促炎性物种的扩大与DN发病和进展有关.
- 来自微生物组的生物标志物可以预测神经病变风险和疼痛表型,独立于血糖控制.
- 基于微生物组的干预措施,如益生菌和便微生物群移植,有望缓解DN症状.
结论:
- 肠道微生物组在糖尿病神经病变的发病过程中发挥着重要作用.
- 微生物组具有作为早期DN诊断和风险分层的工具的潜力.
- 准肠道微生物组为DN管理中的新型治疗策略提供了一个有希望的途径.
相关概念视频
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Chronic Pancreatitis II: Collaborative Care
296
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
296
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
620
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
620
Physiology of Enteric Nervous System and Gut Health
840
The gastrointestinal tract, responsible for the digestion and absorption of nutrients, is safeguarded by the intestinal barrier, which consists of secretory, physical, and immune components. At the forefront is the secretory barrier, composed of essential elements such as mucus, gut microbiota, and defense proteins. They collaborate to break down food particles, facilitate nutrient absorption, and maintain optimal gut health. These secretory components ensure the smooth functioning of the...
840
Psychoneuroimmunology: Diabetes and Cancer
417
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
417
Diabetes: Management and Pharmacotherapy
851
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
851

